You and your family are our top priority. At Fred Hutch Cancer Center, we offer comprehensive and compassionate care — personalized to you. You'll have access to the latest treatment options, clinical ...
The FDA approved Zepzelca with Tecentriq for ES-SCLC, showing improved survival in the IMforte trial. The IMforte trial demonstrated a median overall survival of 13.2 months with the combination ...
The American College of Chest Physicians (CHEST) recently released a new clinical guideline on the management of patients with early-stage non-small cell lung cancer (NSCLC). Published in the journal ...
Scientists have identified proteins that could signal increased lung cancer risk, as well as a drug that could reduce the ...
A new study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center shows that the targeted cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results